GRIP Molecular Technologies
Saint Paul, US · Founded 2019 · Delaware corporation
GRIP Molecular Technologies develops a diagnostic platform built on a CRISPR protease engine that detects pathogen RNA (bacteria, viruses, fungi) from saliva, swab, and urine samples with molecular-grade accuracy in minutes at ambient temperature. It targets point-of-care and point-of-need testing for sexually transmitted, urinary tract, and upper respiratory infections, adaptable to lateral flow, electrochemical, and colorimetric readouts.
Founders & leadership
EG
Edward GillenCEO | CCO
RM
Richard MinicusCFO
BB
Bruce BattenFounder | CSO
Board
EL
Edward LudwigBoard Chairman
MO
Michael OsterholmClinical Advisor
Reported raises · per SEC filings
Form D private placements$9.4M disclosed across 3 rounds · 2019–2023
▶$8.8MraisedMay 2025 · 41 investors · Other TechnologyRule 506(b)
▶$8.8MraisedMay 2025 · 41 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Edward GillenExecutive Officer
- Richard MinicusExecutive Officer
- Bruce BattenExecutive Officer, Director
- Edward LudwigDirector
- Offering amount
- $12M
- Amount sold
- $8.8M
- Minimum investment
- $10K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMay 2023 · 1 investors · Other TechnologyRule 506(b)
▶$500KraisedMay 2023 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce BattenExecutive Officer, Director
- Richard MinicusExecutive Officer
- Edward GillenExecutive Officer
- Edward LudwigDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- First sale
- May 2023
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
▶$100KraisedDec 2020 · 1 investors · Other TechnologyRule 506(b)
▶$100KraisedDec 2020 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Edward GillenExecutive Officer
- Bruce BattenDirector
- Amount sold
- $100K
- First sale
- Nov 2020
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Cepheid4 shared keywordsCepheid manufactures molecular diagnostic instruments and tests that automate PCR-based testing for infectious diseases, oncology, and human genetics. The company serves institutions ranging from central laboratories to near-patient settings with automated diagnostic solutions.
Mediaroom4 shared keywordsMediaRoom is a PR Newswire product that builds branded, fully-hosted online newsrooms for organizations to publish press releases, media coverage, images and videos in one place for journalists, investors and other audiences. It offers custom microsite design, automatic press release posting, social media integration, a content management portal, and SOC 2-compliant hosting with analytics.
Companies competing with GRIP Molecular Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does GRIP Molecular Technologies do?
- GRIP Molecular Technologies develops a diagnostic platform built on a CRISPR protease engine that detects pathogen RNA (bacteria, viruses, fungi) from saliva, swab, and urine samples with molecular-grade accuracy in minutes at ambient temperature. It targets point-of-care and point-of-need testing for sexually transmitted, urinary tract, and upper respiratory infections, adaptable to lateral flow, electrochemical, and colorimetric readouts.
- How much funding has GRIP Molecular Technologies raised?
- GRIP Molecular Technologies has disclosed $9.4M raised across 3 rounds.
- Where is GRIP Molecular Technologies headquartered?
- GRIP Molecular Technologies is headquartered in Saint Paul, US.